Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID S STOKESBERRY

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1427032234
CMS profile
19736
Location
OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$51.29

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $51.29 5

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID S STOKESBERRY

NPI 1427032234 · CMS profile ID 19736

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

OKLAHOMA CITY, OK

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427032234?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427032234?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427032234?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
DAVID S STOKESBERRY, NPI 1427032234, CMS profile ID 19736, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1427032234?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $51.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.9408/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672552169 CMS
Allergan Inc. $13.5007/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671191435 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $11.5606/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684950235 CMS
PFIZER INC. $11.8004/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672231421 CMS
Romark Laboratories, LC $1.4901/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676575015 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $51.29 5
PY2020 $197.03 5
PY2021 $249.67 10
PY2022 $93.99 7
PY2024 $99.26 5
PY2025 $1,843.60 97

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $108,902.60 28
PY2024 Principal investigator $94,981.85 42
PY2023 Principal investigator $412,886.37 49
PY2022 Principal investigator $102,314.36 32
PY2021 Principal investigator $163,880.82 41
PY2020 Principal investigator $333,675.73 83
PY2019 Recipient $39,889.86 5
PY2019 Principal investigator $462,244.42 78

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $124.76 12/31/2021 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792489213
Principal investigator 1 ABBVIE INC. $267.80 12/16/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792487555
Principal investigator 1 ABBVIE INC. $544.30 12/16/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792487557
Principal investigator 1 ABBVIE INC. $7,862.20 12/02/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792485167
Principal investigator 1 ABBVIE INC. $1,788.75 12/02/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn?s Disease who have failed anti-TNF therapy No dispute reported 06/30/2026 792485449
Principal investigator 1 Celgene Corporation $7,324.20 11/23/2021 Non-covered Recipient Entity
Great Lakes Gastroenterology
A Phase 3, Multicenter, Open-Label Extension Trial No dispute reported 06/30/2026 837041565
Principal investigator 1 ABBVIE INC. $6,271.50 11/17/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792483119
Principal investigator 1 ABBVIE INC. $445.50 11/17/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792483121
Principal investigator 1 ABBVIE INC. $1,968.20 11/17/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792483369
Principal investigator 1 ABBVIE INC. $8,321.60 11/09/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792482139
Principal investigator 1 ABBVIE INC. $1,911.30 10/14/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792479437
Principal investigator 1 ABBVIE INC. $3,538.20 10/14/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792479731
Principal investigator 1 ABBVIE INC. $8,960.63 10/13/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn?s Disease who have failed anti-TNF therapy No dispute reported 06/30/2026 792478887
Principal investigator 1 ABBVIE INC. $3,873.90 10/07/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792478571
Principal investigator 1 ABBVIE INC. $1,014.00 09/09/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792475039
Principal investigator 1 ABBVIE INC. $9,320.15 09/07/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792474109
Principal investigator 1 ABBVIE INC. $2,905.50 07/29/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792470347
Principal investigator 1 ABBVIE INC. $1,694.80 07/29/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792470349
Principal investigator 1 ABBVIE INC. $3,783.80 07/29/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792470351
Principal investigator 1 ABBVIE INC. $1,020.50 06/30/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792465337
Principal investigator 1 ABBVIE INC. $1,946.40 06/30/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792465339
Principal investigator 1 ABBVIE INC. $1,029.50 06/30/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792465769
Principal investigator 1 Janssen Research & Development, LLC $118.30 06/28/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787666815
Principal investigator 1 ABBVIE INC. $2,290.90 05/27/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792460753
Principal investigator 1 Janssen Research & Development, LLC $236.60 05/24/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787666799
Principal investigator 1 Roche Products Limited $1,143.00 05/07/2021 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC BUSINESS OFFICE
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 835954853
Principal investigator 1 ABBVIE INC. $11,191.50 05/06/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792455189
Principal investigator 1 ABBVIE INC. $1,739.30 05/06/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792455687
Principal investigator 1 ABBVIE INC. $9,472.00 05/04/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinsons Disease No dispute reported 06/30/2026 792453399
Principal investigator 1 Janssen Research & Development, LLC $9,000.00 05/03/2021 Non-covered Recipient Entity
DIGESTIVE DISEASE SPECIALISTS INC
A Phase 2 Multi Center Randomized Double blind Placebo controlled Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn's Disease No dispute reported 06/30/2026 787653317
Principal investigator 1 ABBVIE INC. $4,931.15 04/30/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792452359
Principal investigator 1 ABBVIE INC. $154.70 04/01/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 792440753
Principal investigator 1 ABBVIE INC. $14,030.70 04/01/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohns Disease No dispute reported 06/30/2026 792441209
Principal investigator 1 ABBVIE INC. $1,778.00 04/01/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis No dispute reported 06/30/2026 792441215
Principal investigator 1 ABBVIE INC. $5,455.10 03/30/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792438043
Principal investigator 1 ABBVIE INC. $41.60 03/03/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 792431749
Principal investigator 1 Janssen Research & Development, LLC $12,551.20 02/15/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787666763
Principal investigator 1 Celgene Corporation $3,472.08 02/11/2021 Non-covered Recipient Entity
Great Lakes Gastroenterology
A Phase 3, Multicenter, Open-Label Extension Study No dispute reported 06/30/2026 807119321
Principal investigator 1 Janssen Research & Development, LLC $6,735.50 01/29/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787666781
Principal investigator 1 ABBVIE INC. $222.00 01/28/2021 Non-covered Recipient Entity
GREAT LAKES MEDICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohns Disease who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 792416145
Principal investigator 1 Celgene Corporation $3,399.70 01/26/2021 Non-covered Recipient Entity
Digestive Disease Specialists, Inc
A Phase 3, Multicenter, Open-Label Extension Trial No dispute reported 06/30/2026 807112133